Profile

William Henry Gmeiner, Ph.D.Wake Forest School of Medicine

William Henry Gmeiner, Ph.D.

Professor,

Contact Information

Academic: 336-716-6216 | Department: 336-716-6216

Email: bgmeiner@wakehealth.edu

Education & Training

  • B.A., University of Chicago, 1982
  • Ph.D., University of Utah, 1989
  • M.B.A., Wake Forest University, 2007
  • Fellowship, University Alberta Medical Sch, 1991

Memberships

  • Am Assn Of Cancer Research
  • Am Chemical Society
  • Am Soc for Pharm & Exper Ther
William Henry Gmeiner, Ph.D.

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Physiology & Pharmacology

Research Interests

DNA; Fluorodeoxyuridylate; Antineoplastic Agents; Antimetabolites, Antineoplastic; Fluorouracil
More »

Contact Information

Academic: 336-716-6216 | Department: 336-716-6216

Email: bgmeiner@wakehealth.edu

Recent Publications

Binding site configurations probe the structure and dynamics of the zinc finger of NEMO (NF-kappaB essential modulator). Godwin RC, Melvin RL, Gmeiner WH, Salsbury FR Jr.. Biochemistry. 2017;56(4):623-633.

Importance of long-time simulations for rare event sampling in zinc finger proteins. Godwin R, Gmeiner W, Salsbury FR Jr.. J Biomol Struct Dyn. 2016;34(1):125-134.

Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. Stuart CH, Singh R, Smith TL, D'Agostino R Jr, Caudell D, Balaji KC, Gmeiner WH.. Nanomedicine (Lond). 2016;11(10):1207-1222.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.. Future Oncol. 2016;12(17):2009-2020.

F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. Gmeiner WH, Gearhart PJ, Pommier Y, Nakamura J.. Future Oncol. 2016;12(19):2183-2188.

All-atom molecular dynamics reveals mechanism of zinc complexation with therapeutic F10. Melvin RL, Gmeiner WH, Salsbury FR Jr.. J Phys Chem B. 2016;120(39):10269-79.

Selection of a novel aptamer against vitronectin using capillary electrophoresis and next generation sequencing. Stuart CH, Riley KR, Boyacioglu O, Herpai DM, Debinski W, Qasem S, Marini FC, Colyer CL, Gmeiner WH.. Mol Ther Nucleic Acids. 2016;5(11):e386.

The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2. Gmeiner WH, Boyacioglu O, Stuart CH, Jennings-Gee J, Balaji KC.. Prostate. 2015;75(4):360-369.

Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS.. Leuk Res. 2015;39(2):229-235.

Influence of zinc-binding on folding and dynamics of zinc finger proteins: in silico [abstract]. Godwin R, Gmeiner W, Salsbury F.. Biophys J. 2015;108(2 Suppl 1):519A.

Small Fdu strand exhibits salt-dependent stability [abstract]. Melvin RL, Gmeiner W, Salsbury FR.. Biophys J. 2015;108(2 Suppl 1):237A.

Disease related mutation effects on conformations and dynamics of the zinc-finger NEMO [abstract]. Godwin R, Gmeiner W, Salsbury F.. Protein Sci. 2015;24(Suppl 1):164-165.

Site-specific DNA-doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells. Stuart CH, Horita DA, Thomas MJ, Salsbury FR Jr, Lively MO, Gmeiner WH.. Bioconjug Chem. 2014;25(2):406-413.

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W.. J Neurooncol. 2014;116(3):447-454.

Non-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with hydrophobicity-dependent DNA release and anti-tumor activity. Ghosh S, Ucer KB, D'Agostino R Jr, Grant K, Sirintrapun J, Thomas MJ, Hantgan R, Bharadwaj M, Gmeiner WH.. Nanomedicine (Lond). 2014;10(2):451-461.

The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH.. Oncotarget. 2014;5(12):4170-4179.

Nanotechnology for cancer treatment. Gmeiner WH, Ghosh S.. Nanotechnology Rev. 2014;3(2):111-122.

F10 inhibits growth of PC3 xenografts and enhances the effects of radiation therapy. Gmeiner WH, Willingham MC, Bourland JD, Hatcher HC, Smith TL, D'Agostino RB Jr, Blackstock W.. J Clin Oncol Res. 2014;2(4):1028.

Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Jennings-Gee J, Pardee TS, Gmeiner WH.. Exp Hematol. 2013;41(2):180-188.

Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity. Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC.. Nucleic Acids Res. 2013;41(8):4650-4659.

Dimeric DNA aptamer complexes for high-capacity-targeted drug delivery using pH-sensitive covalent linkages. Boyacioglu O, Stuart CH, Kulik G, Gmeiner WH.. Mol Ther Nucleic Acids. 2013;2():e107.

Cooperative stabilization of Zn(2+):DNA complexes through netropsin binding in the minor groove of FdU-substituted DNA. Ghosh S, Salsbury FR Jr, Horita DA, Gmeiner WH.. J Biomol Struct Dyn. 2013;31(11):1301-1310.

TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. Huang SY, Murai J, Dalla Rosa I, Dexheimer TS, Naumova A, Gmeiner WH, Pommier Y.. Nucleic Acids Res. 2013;41(16):7793-7803.

Non-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with pH-dependent DNA release and anti-tumor activity [abstract]. Gmeiner WH, Ghosh S, Ucer KB, Williams RT, D'Agostino R, Grant K, Sirintrapun J, Thomas M, Hantgan R, Bharadwaj M.. Cancer Res. 2013;73(8 Suppl 1):ALB-6.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH.. Blood. 2012;119(15):3561-3570.

Carbon nanotubes for cancer therapy. Gmeiner WH. In: Kumar CSSR, ed. Carbon nanomaterials. Weinheim (Germany): Wiley-VCH;2011: 309-332.

Zn2+ selectively stabilizes FdU-substituted DNA through a unique major groove binding motif. Ghosh S, Salsbury FR Jr, Horita DA, Gmeiner WH.. Nucleic Acids Res. 2011;39(10):4490-4498.

The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs. Gmeiner WH, Salsbury F Jr, Olsen CM, Marky LA.. J Nucleic Acids. 2011;2011():631372.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W.. Blood. 2011;118(21):1109-1110.

Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Gmeiner WH, Reinhold WC, Pommier Y.. Mol Cancer Ther. 2010;9(12):3105-3114.

The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W.. Blood. 2010;116(21):1353.

Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. Ghosh S, Dutta S, Gomes E, Carroll D, D'Agostino R Jr, Olson J, Guthold M, Gmeiner WH.. ACS Nano. 2009;3(9):2667-2673.

Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Gmeiner WH, Hellmann GM, Shen P.. Oncol Rep. 2008;19(1):245-251.

MicroPET imaging to monitor tumor response to single agent and combined ionizing radiation therapy and FdUMP treatment [abstract]. Gmeiner WH, Garg S, Hatcher HC, Smith TL, Bourland JD, Garg PK.. J Nucl Med. 2007;48(6 Suppl 2):83P.

Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ.. Oncol Rep. 2007;18(1):287-291.

Genetic determinants for activated fluoropyrimidine chemotherapy. Gmeiner WH.. Drug Dev Res. 2006;67(2):119-129.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Cancer Biology

William Henry Gmeiner, Ph.D.

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Physiology & Pharmacology

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Five Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is RenewedMagnet Hospital Recognition2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.